Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis.
[BACKGROUND] Dasatinib is approved at 100 mg/d for newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).
- 표본수 (n) 83
- 추적기간 73 months
APA
Haddad FG, Jabbour E, et al. (2026). Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis.. Clinical lymphoma, myeloma & leukemia. https://doi.org/10.1016/j.clml.2026.02.013
MLA
Haddad FG, et al.. "Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis.." Clinical lymphoma, myeloma & leukemia, 2026.
PMID
41876352
Abstract
[BACKGROUND] Dasatinib is approved at 100 mg/d for newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). We report outcomes with frontline dasatinib 50 mg/d in a large cohort of patients with CML-CP.
[METHODS] In a phase II clinical trial, patients with newly diagnosed CML-CP received dasatinib 50 mg/d alone (n = 83) or in combination with venetoclax (n = 66). We evaluated the molecular response rates, incidence of adverse events, event-free survival (EFS), and overall survival (OS).
[RESULTS] One hundred forty-nine patients were included; the median age at diagnosis was 46.7 years (range, 19.9-84.3); Sokal risk was high-risk in 7 patients (4.7%). By 60 months of dasatinib therapy, the cumulative rates of major molecular response, MR4, and MR4.5 were 95%, 87%, and 86%, respectively. With a median follow-up of 73 months, the 5-year EFS and OS rates were 96% and 98%, respectively. Adverse events were observed in 72 patients (48%), including pleural effusion in 19 (12.7%), of which 3 (2%) of Grade 3. Eighteen patients (12%) discontinued dasatinib due to adverse events.
[CONCLUSION] The long-term follow-up confirms the safety and efficacy of dasatinib 50 mg/d in patients with newly diagnosed CML-CP.
[METHODS] In a phase II clinical trial, patients with newly diagnosed CML-CP received dasatinib 50 mg/d alone (n = 83) or in combination with venetoclax (n = 66). We evaluated the molecular response rates, incidence of adverse events, event-free survival (EFS), and overall survival (OS).
[RESULTS] One hundred forty-nine patients were included; the median age at diagnosis was 46.7 years (range, 19.9-84.3); Sokal risk was high-risk in 7 patients (4.7%). By 60 months of dasatinib therapy, the cumulative rates of major molecular response, MR4, and MR4.5 were 95%, 87%, and 86%, respectively. With a median follow-up of 73 months, the 5-year EFS and OS rates were 96% and 98%, respectively. Adverse events were observed in 72 patients (48%), including pleural effusion in 19 (12.7%), of which 3 (2%) of Grade 3. Eighteen patients (12%) discontinued dasatinib due to adverse events.
[CONCLUSION] The long-term follow-up confirms the safety and efficacy of dasatinib 50 mg/d in patients with newly diagnosed CML-CP.
같은 제1저자의 인용 많은 논문 (4)
- Mutational Profiling in US Patients With Chronic-phase Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors.
- Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm.
- SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?
- Tyrosine kinase inhibitors, chronic myeloid leukemia, and pregnancy: pharmacotherapeutic challenges and recommendations.